ZA200206467B - 1,2,3,4-tetrahydroisoquinoline derivatives. - Google Patents

1,2,3,4-tetrahydroisoquinoline derivatives. Download PDF

Info

Publication number: ZA200206467B
Authority: ZA; South Africa
Prior art keywords: benzyl; dimethoxy; acetamide; dihydro; isoquinolin
Prior art date: 2000-03-14

Application number

ZA200206467A

Other languages

English (en)

Inventor

Hamed Aissaoui

Martine Clozel

Ralf Koberstein

Michael Cappi

Walter Fischli

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-14

Filing date

2002-08-13

Publication date

2003-11-13

2002-08-13 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2003-11-13 Publication of ZA200206467B publication Critical patent/ZA200206467B/en

Links

UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 45
125000000217 alkyl group Chemical group 0.000 claims description 41
125000000623 heterocyclic group Chemical group 0.000 claims description 20
238000000034 method Methods 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 20
125000003118 aryl group Chemical group 0.000 claims description 19
125000000753 cycloalkyl group Chemical group 0.000 claims description 19
-1 1,2,3,4-tetrahydro-naphthalen-1-yl Chemical group 0.000 claims description 16
125000003342 alkenyl group Chemical group 0.000 claims description 15
125000003710 aryl alkyl group Chemical group 0.000 claims description 15
239000001257 hydrogen Substances 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 15
102000002512 Orexin Human genes 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
108060005714 orexin Proteins 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 13
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
102000008834 Orexin receptor Human genes 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
208000019116 sleep disease Diseases 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 5
239000005557 antagonist Substances 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
101000598921 Homo sapiens Orexin Proteins 0.000 claims description 4
125000003302 alkenyloxy group Chemical group 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
UZJLYRRDVFWSGA-UHFFFAOYSA-N n-benzylacetamide Chemical compound CC(=O)NCC1=CC=CC=C1 UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
JWMZPZFSAXVGMK-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(6-methoxy-2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C12=CC(OC)=CC=C2CCC1NC(=O)CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(OC)C(OC)=C1 JWMZPZFSAXVGMK-UHFFFAOYSA-N 0.000 claims description 2
BVPKSCZDEKFXBF-UHFFFAOYSA-N 2-[8-(cyclopropylmethoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OCC3CC3)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 BVPKSCZDEKFXBF-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 9
239000000126 substance Substances 0.000 claims 5
239000004480 active ingredient Substances 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
239000002671 adjuvant Substances 0.000 claims 2
UOOXDDHYFFXMJJ-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=CC=C2C(NC(=O)C)CCC2=C1 UOOXDDHYFFXMJJ-UHFFFAOYSA-N 0.000 claims 2
GEYCZKOLGCILBP-UHFFFAOYSA-N 2-[1-[(3,4-dichlorophenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-3-ylmethyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CN=C1 GEYCZKOLGCILBP-UHFFFAOYSA-N 0.000 claims 1
GCQCVZZGKIKVTL-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 GCQCVZZGKIKVTL-UHFFFAOYSA-N 0.000 claims 1
RTCVKRBTBBZWQK-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-8-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC(C)C)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 RTCVKRBTBBZWQK-UHFFFAOYSA-N 0.000 claims 1
SNSUCNJUHNKTRE-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-8-propoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C(OCCC)=CC=C(OC)C=2CCN1CC(=O)NCC1=CC=CC=N1 SNSUCNJUHNKTRE-UHFFFAOYSA-N 0.000 claims 1
DBVLOSLXGFOHED-UHFFFAOYSA-N 2-[7-(cyclopropylmethoxy)-1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OCC3CC3)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 DBVLOSLXGFOHED-UHFFFAOYSA-N 0.000 claims 1
IXIVCTNVUGDCGG-UHFFFAOYSA-N 2-[8-(2,2-difluoroethoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OCC(F)F)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 IXIVCTNVUGDCGG-UHFFFAOYSA-N 0.000 claims 1
235000017399 Caesalpinia tinctoria Nutrition 0.000 claims 1
241000388430 Tara Species 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
239000012876 carrier material Substances 0.000 claims 1
238000006482 condensation reaction Methods 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
SGHBDLOMRUXKQF-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)-2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 SGHBDLOMRUXKQF-UHFFFAOYSA-N 0.000 claims 1
LKVQOJRHCJPELL-UHFFFAOYSA-N n-(5-methoxy-2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound COC1=CC=C2C(NC(C)=O)CCC2=C1 LKVQOJRHCJPELL-UHFFFAOYSA-N 0.000 claims 1
AVKSWJBBMWMGSZ-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-diethylphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(CC)C(CC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 AVKSWJBBMWMGSZ-UHFFFAOYSA-N 0.000 claims 1
238000005580 one pot reaction Methods 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
208000002193 Pain Diseases 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 5
125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
208000004454 Hyperalgesia Diseases 0.000 description 3
208000028482 Hypothalamic disease Diseases 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
208000004296 neuralgia Diseases 0.000 description 3
OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 3
OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 3
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
206010002653 Anosmia Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
208000019454 Feeding and Eating disease Diseases 0.000 description 2
201000011240 Frontotemporal dementia Diseases 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
206010021067 Hypopituitarism Diseases 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108050000742 Orexin Receptor Proteins 0.000 description 2
229940123730 Orexin receptor antagonist Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
208000024732 dysthymic disease Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
208000031424 hyperprolactinemia Diseases 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
239000004081 narcotic agent Substances 0.000 description 2
208000021722 neuropathic pain Diseases 0.000 description 2
208000015238 neurotic disease Diseases 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
BPPYYMZLRANARW-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(1-phenylethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NC(C)C1=CC=CC=C1 BPPYYMZLRANARW-UHFFFAOYSA-N 0.000 description 1
TWERMHZJLOWSCE-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(6-methyl-2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NC1C2=CC(C)=CC=C2CC1 TWERMHZJLOWSCE-UHFFFAOYSA-N 0.000 description 1
QXTAWNHYFDPOOV-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-3-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CN=C1 QXTAWNHYFDPOOV-UHFFFAOYSA-N 0.000 description 1
JOFJQVWIZBJLIW-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(4-fluorophenyl)methyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=C(F)C=C1 JOFJQVWIZBJLIW-UHFFFAOYSA-N 0.000 description 1
KWKCDWGGCNCEJD-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(5-methoxy-2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1CC2=CC(OC)=CC=C2C1NC(=O)CN1CCC2=CC(OC)=C(OC(C)C)C=C2C1CC1=CC=C(OC)C(OC)=C1 KWKCDWGGCNCEJD-UHFFFAOYSA-N 0.000 description 1
HMXPWIAPDVKQFN-UHFFFAOYSA-N 2-[7-(2,2-difluoroethoxy)-1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OCC(F)F)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 HMXPWIAPDVKQFN-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
KYHMEWQGAKQCIM-UHFFFAOYSA-N 3-naphthalen-1-ylpropanamide Chemical compound C1=CC=C2C(CCC(=O)N)=CC=CC2=C1 KYHMEWQGAKQCIM-UHFFFAOYSA-N 0.000 description 1
IYOIBZYIRXERTL-UHFFFAOYSA-N 3-pyridin-2-ylpropanamide Chemical compound NC(=O)CCC1=CC=CC=N1 IYOIBZYIRXERTL-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
208000027559 Appetite disease Diseases 0.000 description 1
208000025978 Athletic injury Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
201000009586 Basophil Adenoma Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000001387 Causalgia Diseases 0.000 description 1
208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
201000001498 Froelich syndrome Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
206010018265 Gigantism Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010056438 Growth hormone deficiency Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
206010050515 Hyposmia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
201000007493 Kallmann syndrome Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000006199 Parasomnias Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000007222 Physiological Sexual Dysfunction Diseases 0.000 description 1
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
206010036832 Prolactinoma Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
208000036623 Severe mental retardation Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010041738 Sports injury Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Chemical group 0.000 description 1
208000025371 Taste disease Diseases 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
WCUNEUHOXVBOIJ-UHFFFAOYSA-N [2-[2-(2,3-dihydro-1h-inden-1-ylamino)-2-oxoethyl]-1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-7-yl] n,n-dimethylcarbamate Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC(=O)N(C)C)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 WCUNEUHOXVBOIJ-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005036 alkoxyphenyl group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
235000019558 anosmia Nutrition 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000008827 biological function Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
230000004634 feeding behavior Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
235000019559 hyposmia Nutrition 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
JEQKCODCUDURBW-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC(C)C)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 JEQKCODCUDURBW-UHFFFAOYSA-N 0.000 description 1
INTXFZVWAFGXRO-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)-2-[1-[(3,4-dimethoxyphenyl)methyl]-7-(3-fluoropropoxy)-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OCCCF)=C(OC)C=C2CCN1CC(=O)NC1C2=CC=CC=C2CC1 INTXFZVWAFGXRO-UHFFFAOYSA-N 0.000 description 1
ZQYXICWGEXXFTO-UHFFFAOYSA-N n-(2-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)acetamide Chemical compound C1=CC=C2C(NC(C)=O)C(C)CCC2=C1 ZQYXICWGEXXFTO-UHFFFAOYSA-N 0.000 description 1
ACOHAEBNFWGQCL-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CC=N1 ACOHAEBNFWGQCL-UHFFFAOYSA-N 0.000 description 1
UOOXDDHYFFXMJJ-NSHDSACASA-N n-[(1s)-2,3-dihydro-1h-inden-1-yl]acetamide Chemical compound C1=CC=C2[C@@H](NC(=O)C)CCC2=C1 UOOXDDHYFFXMJJ-NSHDSACASA-N 0.000 description 1
CAXFMDYBAVHPGG-UHFFFAOYSA-N n-benzyl-2-[7-butan-2-yloxy-1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=CC=CC=1CNC(=O)CN1CCC=2C=C(OC)C(OC(C)CC)=CC=2C1CC1=CC=C(OC)C(OC)=C1 CAXFMDYBAVHPGG-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
230000007170 pathology Effects 0.000 description 1
208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
208000026961 psychosexual disease Diseases 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
235000019669 taste disorders Nutrition 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
206010046494 urge incontinence Diseases 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200206467A 2000-03-14 2002-08-13 1,2,3,4-tetrahydroisoquinoline derivatives. ZA200206467B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP0002245		2000-03-14

Publications (1)

Publication Number	Publication Date
ZA200206467B true ZA200206467B (en)	2003-11-13

Family

ID=8163870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200206467A ZA200206467B (en)	2000-03-14	2002-08-13	1,2,3,4-tetrahydroisoquinoline derivatives.

Country Status (18)

Country	Link
US (1)	US6703392B2 (pt)
JP (1)	JP4009460B2 (pt)
KR (2)	KR100842698B1 (pt)
CN (1)	CN100393703C (pt)
AT (1)	ATE286500T1 (pt)
AU (2)	AU6011301A (pt)
BR (1)	BRPI0109200B8 (pt)
CA (1)	CA2402431C (pt)
DE (1)	DE60108236T2 (pt)
ES (1)	ES2234840T3 (pt)
HU (1)	HU227811B1 (pt)
IL (2)	IL150986A0 (pt)
MX (1)	MXPA02008797A (pt)
NO (1)	NO324932B1 (pt)
NZ (1)	NZ520624A (pt)
PT (1)	PT1274687E (pt)
WO (1)	WO2001068609A1 (pt)
ZA (1)	ZA200206467B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2234929T3 (es) *	2000-11-28	2005-07-01	Smithkline Beecham Plc	Derivados de morfolina como antagonistas de los receptores de orexina.
GB0126292D0 (en) *	2001-11-01	2002-01-02	Smithkline Beecham Plc	Compounds
GB0130388D0 (en) *	2001-12-19	2002-02-06	Smithkline Beecham Plc	Compounds
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
JP4528125B2 (ja)	2002-10-11	2010-08-18	アクテリオンファーマシューティカルズリミテッド	スルホニルアミノ−酢酸誘導体
GB0225884D0 (en) *	2002-11-06	2002-12-11	Glaxo Group Ltd	Novel compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
AU2004215409B2 (en) *	2003-02-24	2008-11-20	Merck Sharp & Dohme Corp.	Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
BRPI0408681A (pt) *	2003-03-26	2006-03-28	Actelion Pharmaceuticals Ltd	compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
US7321065B2 (en) *	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
ATE383345T1 (de) *	2003-04-28	2008-01-15	Actelion Pharmaceuticals Ltd	Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
CA2551037A1 (en)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	Novel piperidine derivative
AU2005207856B2 (en) *	2004-01-23	2011-07-14	Janssen Pharmaceutica, N.V.	Novel inhibitors of chymase
US20100048513A1 (en)	2008-08-20	2010-02-25	Hawkins Michael J	Novel inhibitors of chymase
BRPI0508263B8 (pt) *	2004-03-01	2021-05-25	Idorsia Pharmaceuticals Ltd	derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
BRPI0518241A (pt)	2004-11-01	2008-04-22	Amylin Pharmaceuticals Inc	métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
WO2006081522A2 (en) *	2005-01-26	2006-08-03	The Regents Of The Unversity Of California	Modulation of nmda receptor currents via orexin receptor and/or crf receptor
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
US7501395B2 (en)	2005-04-25	2009-03-10	Eisai R & D Management Co., Ltd.	Method of screening for antianxiety drugs
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006129826A1 (ja)	2005-05-30	2006-12-07	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
EP1916239A4 (en)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	PYRIDONE COMPOUND
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
WO2007024004A1 (ja)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	フェニルピリドン誘導体
CA2621470A1 (en)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
US20080255084A1 (en)	2005-10-21	2008-10-16	Randy Lee Webb	Combination of Organic Compounds
WO2007049798A1 (ja)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	新規ベンゾオキサチイン誘導体
EP1953165B1 (en)	2005-11-10	2012-02-01	Msd K.K.	Aza-substituted spiro derivative
ES2376488T3 (es) *	2006-01-26	2012-03-14	Actelion Pharmaceuticals Ltd.	Antibióticos de tetrahidropirano.
UA93903C2 (ru) *	2006-03-15	2011-03-25	Актелион Фармасьютикалз Лтд	Производные тетрагидроизохинолина для повышения функции памяти
PL2010493T3 (pl) *	2006-04-12	2016-08-31	Merck Sharp & Dohme	Pirydyloamidy jako antagoniści kanałów wapniowych typu t
CN101432285A (zh) *	2006-04-26	2009-05-13	埃科特莱茵药品有限公司	作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
US8618102B2 (en)	2006-07-14	2013-12-31	Merck Sharp & Dohme Corp.	Bridged diazepan orexin receptor antagonists
EP2059520B1 (en) *	2006-08-28	2010-02-24	Actelion Pharmaceuticals Ltd.	1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists
EP2946778A1 (en)	2006-09-22	2015-11-25	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en)	2006-09-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
PE20081229A1 (es)	2006-12-01	2008-08-28	Merck & Co Inc	Antagonistas de receptor de orexina de diazepam sustituido
JP2010513466A (ja)	2006-12-22	2010-04-30	アクテリオンファーマシューティカルズリミテッド	５，６，７，８−テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
MX2009010727A (es) *	2007-04-04	2009-10-26	Hoffmann La Roche	Heterociclos como antagonistas de orexina.
EP2150114A4 (en)	2007-05-18	2012-01-18	Merck Sharp & Dohme	OXO-BRIDGED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
WO2008147518A1 (en)	2007-05-23	2008-12-04	Merck & Co., Inc.	Pyridyl piperidine orexin receptor antagonists
JP2010528007A (ja)	2007-05-23	2010-08-19	メルク・シャープ・エンド・ドーム・コーポレイション	シクロプロピルピロリジンオレキシン受容体アンタゴニスト
JP5546451B2 (ja)	2007-06-04	2014-07-09	シナジーファーマシューティカルズインコーポレイテッド	胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PE20091010A1 (es)	2007-10-10	2009-08-08	Actelion Pharmaceuticals Ltd	Derivados de tetrahidroquinolina
US8637513B2 (en)	2007-10-24	2014-01-28	Merck Sharp & Dohme Corp.	Heterocycle phenyl amide T-type calcium channel antagonists
JP5829399B2 (ja) *	2007-12-28	2015-12-09	アクテリオンファーマシューティカルズリミテッドＡｃｔｅｌｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	３置換３，４−ジヒドロ−１ｈ−イソキノリン化合物、その製造方法及びその使用
EP2264026A4 (en)	2008-03-06	2012-03-28	Msd Kk	ALKYLAMINOPYRIDINE DERIVATIVE
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
KR101717145B1 (ko)	2008-05-20	2017-03-16	노이로제스엑스, 인코포레이티드	간보호제 아세트아미노펜 공통 프로드러그
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
WO2009156951A2 (en) *	2008-06-25	2009-12-30	Actelion Pharmaceuticals Ltd	5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
EP2161266A1 (en)	2008-08-22	2010-03-10	EVOTEC Neurosciences GmbH	Benzofuran derivatives as orexin receptor antagonists
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh)	2008-10-31	2011-12-07	默沙东公司	用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010064212A1 (en)	2008-12-05	2010-06-10	Actelion Pharmaceuticals Ltd	Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative
WO2010075068A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20120258957A1 (en)	2009-11-23	2012-10-11	Matilda Jane Bingham	Heterocyclic derivatives
CA2786314A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011138266A1 (en)	2010-05-03	2011-11-10	Evotec Ag	Indolizine and imidazopyridine derivatives as orexin receptor antagonists
WO2011138265A2 (en)	2010-05-03	2011-11-10	Evotec Ag	Indole and indazole derivatives as orexin receptor antagonists
EP2402322A1 (en)	2010-07-02	2012-01-04	Actelion Pharmaceuticals Ltd.	1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (zh)	2011-02-25	2017-04-26	默沙东公司	用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
EP2758060B1 (en)	2011-09-19	2017-11-29	ETH Zürich	Ror gamma modulators for treating diabetes ii complications
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013078413A1 (en) *	2011-11-22	2013-05-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modulators of lipid storage
CA2880901A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014100719A2 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
EP2970119B1 (en)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
EP2781217A1 (en)	2013-03-18	2014-09-24	ETH Zurich	ROR gamma modulators
EP4424697A2 (en)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2016030534A1 (en)	2014-08-29	2016-03-03	Tes Pharma S.R.L.	INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
CN105198809A (zh) *	2015-09-24	2015-12-30	绍兴文理学院	一种2-（1-酰亚胺基甲基）-1,2,3,4-四氢异喹啉衍生物及其合成方法与应用
CN105418498A (zh) *	2015-12-30	2016-03-23	绍兴文理学院	一种1,2,3,4-四氢异喹啉衍生物及其合成方法与应用
EP3454857A1 (en)	2016-05-10	2019-03-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
US10968232B2 (en)	2016-12-20	2021-04-06	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
CN113302189A (zh)	2018-11-20	2021-08-24	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
CN112538100B (zh) *	2020-12-16	2022-06-24	河南中医药大学	一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用
KR102695633B1 (ko) *	2021-12-17	2024-08-14	한국화학연구원	피리미딘을 포함하는 테트라하이드로이소퀴놀린 유도체 및 이의 결핵 치료제 용도
WO2023164596A1 (en) *	2022-02-25	2023-08-31	The Katholieke Universiteit Leuven	Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE204917C (pt)
CA205079A (en) *		1920-10-26	Nelson Lionel	Gas producer
DE261158C (pt)
DE258817C (pt)
CA110459A (en) *	1907-12-09	1908-02-25	Charles Albert Keller	Electric furnace
CA173523A (en) *	1916-04-01	1916-11-28	Raymond B. Price	Textile material
CA170679A (en) *	1916-05-26	1916-07-11	Edwin W. Webb	Car brake
US3480714A (en) *	1966-02-07	1969-11-25	Ciba Geigy Corp	N-substituted isoquinolines as antiprotozoal agents
DD204917A1 (de) *	1981-12-31	1983-12-14	Gerhard Kempter	Verfahren zur herstellung phenylsubstituierter und benzkondensierter cycloalkylaminoacetanilide
JPS6153268A (ja) *	1984-08-24	1986-03-17	Hokuriku Seiyaku Co Ltd	アントラニルアミド誘導体
DD261158A1 (de) *	1987-01-08	1988-10-19	Univ Halle Wittenberg	Verfahren zur herstellung von 2-aminoalkyl-3,4-dihydro-4-oxo-7h-pyrrolo 2.3-d pyrimidinen
DD258817A1 (de) *	1987-01-19	1988-08-03	Univ Halle Wittenberg	Verfahren zur herstellung von 2-(aminoalkyl) -pyrimido-4,5'-5,4 pyrrolo 3,2-f 1,4 thiazepinderivaten
RU2119482C1 (ru)	1991-01-11	1998-09-27	Лаборатуар Глаксо С.А.	Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
DK0707570T3 (da) *	1993-06-22	1998-10-07	Knoll Ag	Isoquinolinderivater som terapeutiske midler
JPH07267961A (ja) *	1994-03-30	1995-10-17	Taisho Pharmaceut Co Ltd	ベンゾフロ［３，２−ｄピリミジン−４−オン誘導体
JPH1095766A (ja)	1996-09-19	1998-04-14	Sanwa Kagaku Kenkyusho Co Ltd	アセトアミド誘導体、及びその用途
IL129744A0 (en) *	1996-11-27	2000-02-29	Pfizer	Apo b-secretion/mtp inhibitory amides
AR016817A1 (es)	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
US6372757B1 (en) *	1998-05-08	2002-04-16	Smithkline Beecham P.L.C.	Phenylurea and phenylthio urea derivatives
WO2000029399A1 (en)	1998-11-12	2000-05-25	Boehringer Ingelheim (Canada) Ltd.	Antiherpes compounds
GB9827467D0 (en) *	1998-12-15	1999-02-10	Zeneca Ltd	Chemical compounds
GB9914015D0 (en) *	1999-06-17	1999-08-18	Zeneca Ltd	Chemical compounds
GB9914025D0 (en) *	1999-06-17	1999-08-18	Zeneca Ltd	Chemical compounds
WO2001002368A1 (en) *	1999-07-06	2001-01-11	Vertex Pharmaceuticals Incorporated	N-heterocyclic derivatives with neuronal activity

2001
- 2001-03-12 AU AU6011301A patent/AU6011301A/xx active Pending
- 2001-03-12 IL IL15098601A patent/IL150986A0/xx active IP Right Grant
- 2001-03-12 NZ NZ520624A patent/NZ520624A/xx not_active IP Right Cessation
- 2001-03-12 KR KR1020027011533A patent/KR100842698B1/ko active IP Right Grant
- 2001-03-12 JP JP2001567703A patent/JP4009460B2/ja not_active Expired - Lifetime
- 2001-03-12 PT PT01933685T patent/PT1274687E/pt unknown
- 2001-03-12 HU HU0300207A patent/HU227811B1/hu unknown
- 2001-03-12 CA CA002402431A patent/CA2402431C/en not_active Expired - Lifetime
- 2001-03-12 DE DE60108236T patent/DE60108236T2/de not_active Expired - Lifetime
- 2001-03-12 US US10/239,693 patent/US6703392B2/en not_active Expired - Lifetime
- 2001-03-12 AU AU2001260113A patent/AU2001260113B2/en not_active Expired
- 2001-03-12 CN CNB018063268A patent/CN100393703C/zh not_active Expired - Lifetime
- 2001-03-12 MX MXPA02008797A patent/MXPA02008797A/es active IP Right Grant
- 2001-03-12 KR KR1020077016214A patent/KR20070087103A/ko active Search and Examination
- 2001-03-12 WO PCT/EP2001/002733 patent/WO2001068609A1/en active IP Right Grant
- 2001-03-12 AT AT01933685T patent/ATE286500T1/de active
- 2001-03-12 BR BRPI0109200A patent/BRPI0109200B8/pt not_active IP Right Cessation
- 2001-03-12 ES ES01933685T patent/ES2234840T3/es not_active Expired - Lifetime
2002
- 2002-07-30 IL IL150986A patent/IL150986A/en unknown
- 2002-08-13 ZA ZA200206467A patent/ZA200206467B/en unknown
- 2002-09-11 NO NO20024339A patent/NO324932B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0300207A3 (en)	2005-07-28
US20030176415A1 (en)	2003-09-18
IL150986A (en)	2007-07-04
WO2001068609A1 (en)	2001-09-20
NZ520624A (en)	2004-02-27
PT1274687E (pt)	2005-04-29
HU227811B1 (en)	2012-03-28
US6703392B2 (en)	2004-03-09
IL150986A0 (en)	2003-02-12
WO2001068609B1 (en)	2002-02-21
ATE286500T1 (de)	2005-01-15
CN1416420A (zh)	2003-05-07
AU2001260113B2 (en)	2006-04-06
JP4009460B2 (ja)	2007-11-14
MXPA02008797A (es)	2005-09-08
CA2402431A1 (en)	2001-09-20
KR100842698B1 (ko)	2008-07-01
ES2234840T3 (es)	2005-07-01
DE60108236T2 (de)	2005-12-22
KR20020080465A (ko)	2002-10-23
NO324932B1 (no)	2008-01-07
BR0109200A (pt)	2003-06-03
KR20070087103A (ko)	2007-08-27
NO20024339L (no)	2002-09-11
HUP0300207A2 (en)	2003-05-28
CA2402431C (en)	2009-10-06
NO20024339D0 (no)	2002-09-11
CN100393703C (zh)	2008-06-11
AU6011301A (en)	2001-09-24
JP2003527374A (ja)	2003-09-16
BRPI0109200B8 (pt)	2021-05-25
DE60108236D1 (de)	2005-02-10
BRPI0109200B1 (pt)	2015-08-11

Publication	Publication Date	Title
ZA200206467B (en)	2003-11-13	1,2,3,4-tetrahydroisoquinoline derivatives.
US7067519B2 (en)	2006-06-27	7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
AU2001260113A1 (en)	2001-12-06	1,2,3,4-tetrahydroisoquinoline derivatives
CA2557163A1 (en)	2005-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US7192950B2 (en)	2007-03-20	Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
CN1332942C (zh)	2007-08-22	磺酰基氨基－乙酸衍生物及其作为阿立新受体拮抗剂的应用
US20060178515A1 (en)	2006-08-10	Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
RU2009109150A (ru)	2010-09-27	Соединения аэетина в качестве антагонистов рецептора орексина
EP2870144B1 (en)	2017-04-19	Orexin receptor antagonists
US7538109B2 (en)	2009-05-26	Quinoxalin-3-one derivatives as orexin receptor antagonists
WO2013169610A1 (en)	2013-11-14	Process for the preparation of an intermediate for an orexin receptor antagonist
CN101384604B (zh)	2012-08-08	乙醇或乙二醇环己基抗菌素衍生物
EP1274687B1 (en)	2005-01-05	1,2,3,4- tetrahydroisoquinoline derivatives
WO2017073710A1 (ja)	2017-05-04	モルヒナン誘導体及びその医薬用途
EP1620409A1 (en)	2006-02-01	Quinoxalin-3-one derivatives as orexin receptor antagonists
MXPA06009833A (en)	2007-04-10	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives